Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein with KRAB and SCAN domains 4 (ZKSCAN4) is a transcription factor from the C2H2 zinc finger protein family. It is characterized by KRAB and SCAN domains, which confer abilities for transcriptional repression and protein-protein interactions. ZKSCAN4 binds DNA in a sequence-specific manner, regulating gene expression—especially through RNA polymerase II. It has roles in chromatin remodeling and can impact cellular stress responses. Research indicates ZKSCAN4 affects synaptic function and resilience to chronic stress in the hippocampus, and may contribute to psychiatric disorders and cancer progression. While it is recognized as a potential therapeutic target due to its involvement in key transcriptional axes, no approved drugs or clinical biomarkers directly target ZKSCAN4[1][2][3][4][5][6].
Not applicable for any approved drugs; in principle, inhibition or activation could modulate its transcriptional regulatory activity (e.g., targeted inhibition could upregulate ZKSCAN4-repressed genes such as Htr2a)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein with KRAB and SCAN domains 4 (ZKSCAN4).